Development and Optimization of Indirect ELISAs for the Detection of Anti-Capripoxvirus Antibodies in Cattle, Sheep, and Goat Sera.
A34
A36
GTPV
LSDV
SPPV
capripoxvirus
iELISA
Journal
Microorganisms
ISSN: 2076-2607
Titre abrégé: Microorganisms
Pays: Switzerland
ID NLM: 101625893
Informations de publication
Date de publication:
30 Sep 2022
30 Sep 2022
Historique:
received:
01
08
2022
revised:
26
09
2022
accepted:
27
09
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
28
10
2022
Statut:
epublish
Résumé
Sheeppox (SPP), goatpox (GTP), and lumpy skin disease (LSD) are economically significant pox diseases of ruminants, caused by sheeppox virus (SPPV), goatpox virus (GTPV), and lumpy skin disease virus (LSDV), respectively. SPPV and GTPV can infect both sheep and goats, while LSDV mainly affects cattle. The recent emergence of LSD in Asia and Europe and the repeated incursions of SPP in Greece, Bulgaria, and Russia highlight how these diseases can spread outside their endemic regions, stressing the urgent need to develop high-throughput serological surveillance tools. We expressed and tested two recombinant truncated proteins, the capripoxvirus homologs of the vaccinia virus C-type lectin-like protein A34 and the EEV glycoprotein A36, as antigens for an indirect ELISA (iELISA) to detect anti-capripoxvirus antibodies. Since A34 outperformed A36 by showing no cross-reactivity to anti-parapoxvirus antibodies, we optimized an A34 iELISA using two different working conditions, one for LSD in cattle and one for SPP/GTP in sheep and goats. Both displayed sound sensitivities and specificities: 98.81% and 98.72%, respectively, for the LSD iELISA, and 97.68% and 95.35%, respectively, for the SPP/GTP iELISA, and did not cross-react with anti-parapoxvirus antibodies of cattle, sheep, and goats. These assays could facilitate the implementation of capripox control programs through serosurveillance and the screening of animals for trade.
Identifiants
pubmed: 36296232
pii: microorganisms10101956
doi: 10.3390/microorganisms10101956
pmc: PMC9608586
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
EFSA J. 2018 Oct 16;16(10):e05452
pubmed: 32625728
Transbound Emerg Dis. 2018 Dec;65(6):1514-1521
pubmed: 29749049
Epidemiol Infect. 1995 Feb;114(1):219-26
pubmed: 7867740
Onderstepoort J Vet Res. 2017 Mar 28;84(1):e1-e6
pubmed: 28397517
PLoS One. 2013 Oct 07;8(10):e75971
pubmed: 24116084
J Wildl Dis. 2021 Apr 1;57(2):439-442
pubmed: 33822163
Onderstepoort J Vet Res. 2005 Jun;72(2):153-64
pubmed: 16137133
J Virol. 2001 Aug;75(15):7122-30
pubmed: 11435593
Microorganisms. 2021 May 26;9(6):
pubmed: 34073392
J Virol Methods. 2008 Aug;151(2):225-229
pubmed: 18582954
BMC Vet Res. 2013 May 01;9:90
pubmed: 23634704
J Gen Virol. 2009 Aug;90(Pt 8):1967-1977
pubmed: 19339476
Prev Vet Med. 2021 Nov;196:105473
pubmed: 34479042
Stat Med. 2012 Oct 15;31(23):2676-86
pubmed: 22307964
J Virol. 1992 Mar;66(3):1610-21
pubmed: 1738204
Lett Appl Microbiol. 1998 Aug;27(2):76-8
pubmed: 9750326
Virology. 1999 Feb 1;254(1):71-80
pubmed: 9927575
Viruses. 2020 Sep 28;12(10):
pubmed: 32998423
J Immunol Methods. 2012 Oct 31;384(1-2):148-51
pubmed: 22732194
Transbound Emerg Dis. 2017 Jun;64(3):729-745
pubmed: 26564428
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
J Virol. 1997 May;71(5):3904-15
pubmed: 9094667
Transbound Emerg Dis. 2019 Jan;66(1):181-185
pubmed: 30126058
J Clin Microbiol. 2008 Feb;46(2):438-42
pubmed: 18032617
J Virol Methods. 2009 Oct;161(1):19-29
pubmed: 19426763
J Virol Methods. 1994 Oct;49(3):285-94
pubmed: 7868646
Am J Epidemiol. 2006 Apr 1;163(7):670-5
pubmed: 16410346
Mol Cell Probes. 2018 Feb;37:48-54
pubmed: 29158139
J Immunol Methods. 1999 Jul 30;227(1-2):187-96
pubmed: 10485266
PLoS One. 2016 Apr 28;11(4):e0153688
pubmed: 27123588
BMC Bioinformatics. 2011 Mar 17;12:77
pubmed: 21414208
Transbound Emerg Dis. 2012 Feb;59(1):40-8
pubmed: 21749675
Transbound Emerg Dis. 2009 May;56(4):132-41
pubmed: 19281604
Vet Microbiol. 2011 Apr 21;149(1-2):30-9
pubmed: 21115310
J Virol Methods. 2011 Jan;171(1):134-40
pubmed: 21029751
Vaccine. 2014 Jun 24;32(30):3772-9
pubmed: 24837763
J Virol. 2002 Jun;76(12):6054-61
pubmed: 12021338
Virol J. 2010 Sep 21;7:245
pubmed: 20854693
Sci Rep. 2019 Apr 30;9(1):6646
pubmed: 31040355